Literature DB >> 8901418

RET mutations in human disease.

B Pasini1, I Ceccherini, G Romeo.   

Abstract

The RET proto-oncogene is at the origin of one of the most interesting models of human disease caused by mutations in a receptor tyrosine kinase gene. Somatic rearrangements of RET are involved in the aetiology of a variable proportion of papillary thyroid carcinomas (PTC), the most common type of thyroid tumour whose prevalence is increasing in areas heavily exposed to radioactive fallout after the Chernobyl accident of 1986. Moreover, germline RET mutations are associated with the three variants of the inherited cancer syndrome known as multiple endocrine neoplasia type 2 (MEN2A, MEN2B and FMTC). Finally, RET mutations or heterozygous deletions of the whole gene cause the autosomal dominant form of Hirschsprung disease (HSCR), a congenital disorder of the enteric nervous system (ENS).

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8901418     DOI: 10.1016/0168-9525(96)10012-3

Source DB:  PubMed          Journal:  Trends Genet        ISSN: 0168-9525            Impact factor:   11.639


  21 in total

Review 1.  Molecular mechanisms of RET activation in human neoplasia.

Authors:  M Santoro; F Carlomagno; R M Melillo; M Billaud; G Vecchio; A Fusco
Journal:  J Endocrinol Invest       Date:  1999-11       Impact factor: 4.256

Review 2.  Dependence receptors: between life and death.

Authors:  P Mehlen; C Thibert
Journal:  Cell Mol Life Sci       Date:  2004-08       Impact factor: 9.261

3.  Shc and Enigma are both required for mitogenic signaling by Ret/ptc2.

Authors:  K Durick; G N Gill; S S Taylor
Journal:  Mol Cell Biol       Date:  1998-04       Impact factor: 4.272

4.  The null oncogene hypothesis and protection from cancer.

Authors:  M P Davenport; R L Ward; N J Hawkins
Journal:  J Med Genet       Date:  2002-01       Impact factor: 6.318

5.  Glial cell line-derived neurotrophic factor-dependent RET activation can be mediated by two different cell-surface accessory proteins.

Authors:  M Sanicola; C Hession; D Worley; P Carmillo; C Ehrenfels; L Walus; S Robinson; G Jaworski; H Wei; R Tizard; A Whitty; R B Pepinsky; R L Cate
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-10       Impact factor: 11.205

6.  The sensitivity of activated Cys Ret mutants to glial cell line-derived neurotrophic factor is mandatory to rescue neuroectodermic cells from apoptosis.

Authors:  B Mograbi; R Bocciardi; I Bourget; T Juhel; D Farahi-Far; G Romeo; I Ceccherini; B Rossi
Journal:  Mol Cell Biol       Date:  2001-10       Impact factor: 4.272

7.  A gene predisposing to familial thyroid tumors with cell oxyphilia maps to chromosome 19p13.2.

Authors:  F Canzian; P Amati; H R Harach; J L Kraimps; F Lesueur; J Barbier; P Levillain; G Romeo; D Bonneau
Journal:  Am J Hum Genet       Date:  1998-12       Impact factor: 11.025

Review 8.  Potential applications of molecular biology in neuroendocrine tumors.

Authors:  Tommaso Emmer; Marco Volante; Alberto Pagani; Elena Allia; Pellegrino Crafa; Gianni Bussolati
Journal:  Endocr Pathol       Date:  2003       Impact factor: 3.943

9.  Permanent neonatal diabetes caused by dominant, recessive, or compound heterozygous SUR1 mutations with opposite functional effects.

Authors:  Sian Ellard; Sarah E Flanagan; Christophe A Girard; Ann-Marie Patch; Lorna W Harries; Andrew Parrish; Emma L Edghill; Deborah J G Mackay; Peter Proks; Kenju Shimomura; Holger Haberland; Dennis J Carson; Julian P H Shield; Andrew T Hattersley; Frances M Ashcroft
Journal:  Am J Hum Genet       Date:  2007-06-29       Impact factor: 11.025

Review 10.  Hirschsprung's disease: clinical dysmorphology, genes, micro-RNAs, and future perspectives.

Authors:  Consolato Maria Sergi; Oana Caluseriu; Hunter McColl; David D Eisenstat
Journal:  Pediatr Res       Date:  2016-09-28       Impact factor: 3.756

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.